Discordant Response of Systemic Mastocytosis Associated With Myelodysplastic Syndrome After Midostaurin and Allogeneic Hematopoietic Stem-cell Transplantation
Main Authors: | Marion Haas, Roch Houot, Francisco Llamas-Gutierrez, Marie-Laure Boulland, Mikael Roussel, Thierry Lamy, Thierry Fest, Cedric Pastoret |
---|---|
Format: | Article |
Language: | English |
Published: |
Wolters Kluwer
2020-12-01
|
Series: | HemaSphere |
Online Access: | http://journals.lww.com/10.1097/HS9.0000000000000478 |
Similar Items
-
Clinical potential of midostaurin in advanced systemic mastocytosis
by: Chandesris MO, et al.
Published: (2017-05-01) -
Real-World Efficacy of Midostaurin in Aggressive Systemic Mastocytosis
by: Aneta Szudy-Szczyrek, et al.
Published: (2021-03-01) -
A case of aggressive systemic mastocytosis with bulky lymphadenopathy showing response to midostaurin
by: Mariarita Sciumè, et al.
Published: (2021-02-01) -
European Medicines Agency review of midostaurin (Rydapt) for the treatment of adult patients with acute myeloid leukaemia and systemic mastocytosis
by: Yang Yu, et al.
Published: (2019-11-01) -
Spotlight on midostaurin in the treatment of FLT3-mutated acute myeloid leukemia and systemic mastocytosis: design, development, and potential place in therapy
by: Weisberg E, et al.
Published: (2017-12-01)